Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 2
1992 6
1993 4
1994 4
1995 1
1996 2
1997 8
1998 3
1999 2
2000 1
2001 6
2002 8
2003 14
2004 6
2005 12
2006 15
2007 10
2008 13
2009 14
2010 12
2011 19
2012 19
2013 26
2014 20
2015 12
2016 10
2017 9
2018 5
2019 2
2020 4
2021 3
2022 2
2025 1
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Results by year

Filters applied: . Clear all
Page 1
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA; SENIORS Investigators. Flather MD, et al. Eur Heart J. 2005 Feb;26(3):215-25. doi: 10.1093/eurheartj/ehi115. Epub 2005 Jan 9. Eur Heart J. 2005. PMID: 15642700 Clinical Trial.
There was no significant influence of age, gender, or ejection fraction on the effect of nebivolol on the primary outcome. Death (all causes) occurred in 169 (15.8%) on nebivolol and 192 (18.1%) on placebo (HR 0.88, 95% CI 0.71-1.08; P=0.21). CONCLUSION: Nebivolo …
There was no significant influence of age, gender, or ejection fraction on the effect of nebivolol on the primary outcome. Death (all …
Model-informed dose optimization of carvedilol and nebivolol in cirrhotic patients: a pilot randomized clinical study.
Tarek M, Ali AA, Biomy R, Abdelkawy K, El-Khateeb E. Tarek M, et al. Sci Rep. 2026 Jun 16;16(1):18663. doi: 10.1038/s41598-026-56578-3. Sci Rep. 2026. PMID: 42297946 Free PMC article. Clinical Trial.
This study evaluated the efficacy and safety of PBPK-guided dosing of carvedilol and nebivolol in cirrhotic patients. First, PBPK models were validated using clinical pharmacokinetic data from healthy volunteers and optimized for cirrhosis, then applied to simulate unteste …
This study evaluated the efficacy and safety of PBPK-guided dosing of carvedilol and nebivolol in cirrhotic patients. First, PBPK mod …
Comprehensive Assessment of Coronary Plaque Progression With Advanced Intravascular Imaging, Physiological Measures, and Wall Shear Stress: A Pilot Double-Blinded Randomized Controlled Clinical Trial of Nebivolol Versus Atenolol in Nonobstructive Coronary Artery Disease.
Hung OY, Molony D, Corban MT, Rasoul-Arzrumly E, Maynard C, Eshtehardi P, Dhawan S, Timmins LH, Piccinelli M, Ahn SG, Gogas BD, McDaniel MC, Quyyumi AA, Giddens DP, Samady H. Hung OY, et al. J Am Heart Assoc. 2016 Jan 25;5(1):e002764. doi: 10.1161/JAHA.115.002764. J Am Heart Assoc. 2016. PMID: 26811165 Free PMC article. Clinical Trial.
Nebivolol patients had decreased lumen and vessel areas along with increased plaque area, resulting in more constrictive remodeling (P=0.002). ...Importantly, after adjusting for beta-blocker, low-WSS segments remained significantly associated with lumen loss and plaque pr …
Nebivolol patients had decreased lumen and vessel areas along with increased plaque area, resulting in more constrictive remodeling ( …
The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial.
Studinger P, Tabák ÁG, Chen CH, Salvi P, Othmane TE, Torzsa P, Kapocsi J, Fekete BC, Tislér A. Studinger P, et al. J Clin Hypertens (Greenwich). 2013 Dec;15(12):910-7. doi: 10.1111/jch.12210. Epub 2013 Oct 4. J Clin Hypertens (Greenwich). 2013. PMID: 24119182 Free PMC article. Clinical Trial.
AIx remained unchanged, while AIx@75 decreased significantly by 5.4% 2.5% in the nebivolol group. According to general linear models, individual change in heart rate was a strong predictor of change in AIx in the carvedilol group (r(2) =0.23, P=.03) although no similar ass …
AIx remained unchanged, while AIx@75 decreased significantly by 5.4% 2.5% in the nebivolol group. According to general linear models, …
Managing endothelial dysfunction in COVID-19 with statins, beta blockers, nicorandil, and oral supplements: A pilot, double-blind, placebo-controlled, randomized clinical trial.
Matli K, Al Kotob A, Jamaleddine W, Al Osta S, Salameh P, Tabbikha R, Chamoun N, Moussawi A, Saad JM, Atwi G, Saad TA, Jamal O, Mokhbat J, Ghanem G. Matli K, et al. Clin Transl Sci. 2022 Oct;15(10):2323-2330. doi: 10.1111/cts.13369. Epub 2022 Jul 20. Clin Transl Sci. 2022. PMID: 35808843 Free PMC article. Clinical Trial.
In this pilot, double-blind, placebo-controlled, randomized clinical trial, we assigned patients who were admitted to the hospital with mild, moderate, or severe COVID-19 infection to receive, on top of optimal medical therapy, either an endothelial protocol consisting of (Nicora …
In this pilot, double-blind, placebo-controlled, randomized clinical trial, we assigned patients who were admitted to the hospital with mild …
Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial.
Uhlir O, Dvorak I, Gregor P, Malek I, Spinarova L, Vojacek J, Van Nueten L. Uhlir O, et al. J Card Fail. 1997 Dec;3(4):271-6. doi: 10.1016/s1071-9164(97)90026-9. J Card Fail. 1997. PMID: 9547441 Clinical Trial.
One patient on nebivolol 2.5 mg developed hypotension and pulmonary edema, and one patient on nebivolol 5 mg, bradycardia. ...CONCLUSIONS: In view of increasing interest in beta-blockade in heart failure, nebivolol merits further study in this context. The ca …
One patient on nebivolol 2.5 mg developed hypotension and pulmonary edema, and one patient on nebivolol 5 mg, bradycardia. ... …
Nebivolol and metoprolol: long-term effects on inflammation and oxidative stress in essential hypertension.
Serg M, Kampus P, Kals J, Zagura M, Zilmer M, Zilmer K, Kullisaar T, Eha J. Serg M, et al. Scand J Clin Lab Invest. 2012 Sep;72(5):427-32. doi: 10.3109/00365513.2012.691991. Epub 2012 Jun 18. Scand J Clin Lab Invest. 2012. PMID: 22708640 Clinical Trial.
Nebivolol and metoprolol reduced equally significantly brachial blood pressure. The oxLDL was significantly reduced in both groups (p < 0.01 and for both drugs), but only nebivolol reduced 8-isoprostanes (p = 0.01). ...These data suggest that in long-term antihyp …
Nebivolol and metoprolol reduced equally significantly brachial blood pressure. The oxLDL was significantly reduced in both groups (p …
Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients.
Poirier L, Cléroux J, Nadeau A, Lacourcière Y. Poirier L, et al. J Hypertens. 2001 Aug;19(8):1429-35. doi: 10.1097/00004872-200108000-00011. J Hypertens. 2001. PMID: 11518851 Clinical Trial.
OBJECTIVES: To compare the effects of nebivolol and atenolol in 25 ambulatory hypertensive patients with impaired glucose tolerance. ...Neither drug induced systemic or forearm vasodilatation but the inverse relationship between cardiac output and insulin sensitivity was p …
OBJECTIVES: To compare the effects of nebivolol and atenolol in 25 ambulatory hypertensive patients with impaired glucose tolerance. …
Differential Effects of Antihypertensive Drugs on Central Blood Pressure: A Randomized Comparison Between Nebivolol and Telmisartan.
Lim S, Kook H, Yu CW, Kim JH, Cha JJ, Joo HJ, Na JO, Choi CU, Lim SY, Park JH, Hong SJ, Lim DS. Lim S, et al. Am J Hypertens. 2026 Feb 1;39(2):303-311. doi: 10.1093/ajh/hpaf098. Am J Hypertens. 2026. PMID: 40490940 Free article. Clinical Trial.

Heart rate at week 12 was significantly lower in the nebivolol group than that in the telmisartan group (64.2 11 vs. 74.6 11 beats per minute, P < 0.001). CONCLUSIONS: Nebivolol was less effective than telmisartan at reducing cSBP. CLINICAL TRIAL REGISTRATION

…
Heart rate at week 12 was significantly lower in the nebivolol group than that in the telmisartan group (64.2 11 vs. 74.6 11 beat …
Exercise tolerance with nebivolol and atenolol.
Van Bortel LM, van Baak MA. Van Bortel LM, et al. Cardiovasc Drugs Ther. 1992 Jun;6(3):239-47. doi: 10.1007/BF00051145. Cardiovasc Drugs Ther. 1992. PMID: 1353367 Clinical Trial.
At these dosages nebivolol shows a smaller decrease in heart rate than atenolol. During exercise, the rise in systolic blood pressure and heart rate is less depressed with nebivolol than with atenolol. ...Changes in hemodynamics influence maximal exercise capacity. …
At these dosages nebivolol shows a smaller decrease in heart rate than atenolol. During exercise, the rise in systolic blood pressure …
247 results